Nuwellis (NUWE) Net Income towards Common Stockholders (2011 - 2026)
Nuwellis (NUWE) posted Net Income towards Common Stockholders of -$4.5 million for Q1 2026, down 87.48% on a QoQ basis from -$2.4 million in Q4 2025, and down 50.65% year-over-year from -$9.2 million in Q1 2025.
Nuwellis (NUWE) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends
Nuwellis' Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at -$4.5 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 50.65% year-over-year to -$4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.0 million (down 93.37% YoY) and the FY2025 annual result came in at -$17.5 million, down 64.88% from the prior year.
- Net Income towards Common Stockholders was -$4.5 million for Q1 2026 at Nuwellis, down from -$2.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $2.4 million in Q3 2024 and bottomed at -$12.6 million in Q2 2025.
- A 5-year average of -$4.1 million and a median of -$3.9 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders plunged 476.93% — and 2024, when it surged 169.97%.
- Nuwellis' Net Income towards Common Stockholders stood at -$1.4 million in 2022, then plunged by 476.93% to -$7.9 million in 2023, then surged by 81.48% to -$1.5 million in 2024, then tumbled by 64.92% to -$2.4 million in 2025, then slumped by 87.48% to -$4.5 million in 2026.
- Business Quant data shows NUWE's Net Income towards Common Stockholders at -$4.5 million in Q1 2026, -$2.4 million in Q4 2025, and $469000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Nuwellis | 117,386.28 | -1.97 Mn | 1.68 Mn | -4.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.54 Mn |
| Dec 31, 2025 | -2.42 Mn |
| Sep 30, 2025 | 469,000.00 |
| Jun 30, 2025 | -12.55 Mn |
| Mar 31, 2025 | -3.01 Mn |
| Dec 31, 2024 | -1.47 Mn |
| Sep 30, 2024 | 2.36 Mn |
| Jun 30, 2024 | -7.73 Mn |
| Mar 31, 2024 | -3.79 Mn |
| Dec 31, 2023 | -7.93 Mn |
| Sep 30, 2023 | -3.37 Mn |
| Jun 30, 2023 | -4.85 Mn |
| Mar 31, 2023 | -6.49 Mn |
| Dec 31, 2022 | -1.37 Mn |
| Sep 30, 2022 | -3.87 Mn |
| Jun 30, 2022 | -4.29 Mn |
| Mar 31, 2022 | -4.47 Mn |
| Dec 31, 2021 | 15.82 Mn |
| Sep 30, 2021 | -5.27 Mn |
| Jun 30, 2021 | -4.73 Mn |